Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects
Open Access
- 1 February 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (2) , 788-790
- https://doi.org/10.1128/aac.50.2.788-790.2006
Abstract
The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma and skin blister fluid. The mean penetration of telavancin into blister fluid was 40%. This study reveals that adequate concentrations are achieved in both plasma and blister fluid for pathogens frequently implicated in skin and soft tissue infections.Keywords
This publication has 13 references indexed in Scilit:
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous AdministrationsAntimicrobial Agents and Chemotherapy, 2005
- Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium sppAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of TD-6424 againstStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- Semi-synthetic glycopeptide antibacterialsBioorganic & Medicinal Chemistry Letters, 2003
- Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapyInternational Journal of Antimicrobial Agents, 2003
- Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister FluidAntimicrobial Agents and Chemotherapy, 2003
- Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance studyDiagnostic Microbiology and Infectious Disease, 2002
- Treatment of skin and soft-tissue infections.1995